Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

American Cancer Society Relay For Life Of Second Life Marks Milestone Year In Virtual World
Celebrating its fifth year in the virtual world, the 2009 American Cancer Society Relay For Life of Second Life is set for July 18-19 as avatars representing cancer survivors, caregivers, their families and the millions of passionate supporters gather virtually to celebrate the lives of those who have battled cancer, remember loved ones lost, and join the American Cancer Society in fighting for every birthday, threatened by every cancer in every community.
generic viagra online
Gathering Of Swine Flu Experts At New York Academy Of Sciences May 28
The very latest information on the 2009 swine influenza (H1N1) outbreak is the subject of a landmark afternoon symposium hosted by the New York Academy of Sciences today, Thursday, May 28. Speakers will discuss the new recombinant virus, epidemiology, treatment, vaccine development and the public health implications of a worldwide pandemic.
News of the day
Simulating The Pandemic Disease Airport Screening System
Four major US national laboratories have worked together to develop a computer model to help airport authorities screen passengers for pandemic influenza. The tool can help estimate false negatives, people with influenza who slip through the screening process, and so assess the risk of infected passengers unknowingly spreading disease across the nation.
Health Insurance

Spectrum Pharmaceuticals Receives Complete Response Letter From FDA For Zevalin

Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental Biologics License Application (sBLA) for ZEVALIN® (ibritumomab tiuxetan) in the first-line consolidation setting for non-Hodgkin"s Lymphoma (NHL) patients. The Prescription Drug User Fee Act (PDUFA) Action Date for the ZEVALIN sBLA in the first-line consolidation setting was July 2, 2009. ZEVALIN is currently FDA approved and marketed by Spectrum for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL, including patients who have rituximab-refractory follicular NHL. The FDA requested the Company to submit data files from the FIT study to support and verify a subset of the data that are currently under review to support the proposed labeling. Importantly: 1) No additional clinical studies have been requested; 2) The additional data requested do not involve new data analyses; 3) The Company plans to formally respond to the FDA"s requests by this Wednesday, July 8, 2009. Spectrum is confident that the data it will submit will satisfy the requirements of the Complete Response letter, and, at this time, continues to expect a favorable regulatory decision. Spectrum Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009